DWTX says Halneuron shows durable efficacy in chemotherapy neuropathic pain
DWTX’s Halneuron, a selective NaV1.7 inhibitor, is described as targeting chemotherapy-induced neuropathic pain with durable efficacy and strong tolerability in clinical trials. Company says synthetic TTX manufacturing supports supply and IP, with phase III and NDA milestones planned.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.